Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

類似資料

• Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation
  著者:: Hayashi, Hidetoshi, 等
  出版事項: (2016)
• Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
  著者:: Takeda, Masayuki, 等
  出版事項: (2018)
• Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
  著者:: Hayashi, Hidetoshi, 等
  出版事項: (2011)
• A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
  著者:: Makuuchi, Yosuke, 等
  出版事項: (2018)
• Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
  著者:: Takeda, Masayuki, 等
  出版事項: (2019)